Alzheimer's Disease
Conditions
Keywords
endurance training, BDNF analysis, cognitive function, physiological abilities
Brief summary
Alzheimer's disease (AD) is a neurodegenerative disease leading to one of the most common forms of dementia in humans and memory disorder is one of the first symptoms that lead to diagnosis.
Detailed description
Present in greater amounts in the regions of the hippocampus and cortex, the Brain-derived neurotrophic factor (BDNF) is essential to both learning and memory processes. This protein is found in lower amounts in people with AD. Acute physical activity of moderate to vigorous intensity would increase the levels of plasma BDNF whether for a healthy person or a person with AD. Nevertheless in rest, healthy people have higher level of BDNF than individuals with AD. There are no studies on the effect of chronic exercise based on BDNF level at rest in people with AD. In a hypothetical endurance training of 18 sessions, whether interval or continuous training the levels of BDNF would increase in people with AD at rest. Their physiological and neuropsychological performances would also show a rise.
Interventions
DEVICEEndurance Training
40 people will submitted to endurance training: 20 will perform a continuous training and 20 will perform an interval training. The variables that will be analyzed are maximum aerobic power, endurance, heart rate, prehension strength, Mini-Mental State Examination (MMSE), REY's test, biological examination and level of BDNF plasma, before and after the intervention and one month after the end of the intervention and one month after the end of the intervention.
OTHERtherapeutic education meetings
Group of 20 people will be the control group and will not perform ET. However, they will have 9 therapeutic education meetings.
Sponsors
University Hospital Center of Martinique
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* Alzheimer's disease patients diagnosed by a consultation memory (DSM- IV) * Person with at least 60 years * Person with a score higher than 15 in the Mini Mental State Examination * No one can achieve the pedaling motion * People who do not perform regular physical activity on bike * Nobody has given free and informed consent in writing or obtained from a trusted person or the family environment * People affiliated to a social security
Exclusion criteria
* Patient who refused to provide written consent * Inability to pedal * Recent myocardial necrosis (less than 3 months) * Aortic Stenosis * Uncompensated heart failure * Unstable angina * Ventricular arrythmia * Pulmonary embolism * Coxarthrosis, knee, ankle osteoarthritis * Not affiliated to a social security * Patient already participating in another biomedical research
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Measuring the effect of a program of endurance training (ET), on the levels of plasma BDNF. | Up to 4 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Measuring the effect of training on the psychological performance by using questionnaire MMSE | Up to 4 months | — |
| Measuring the effect of training on the psychological performance by using questionnaire: Rey auditory verbal learning test (RAVLT) | Up to 4 months | — |
| Measuring the effect of training on the psychological performance by using questionnaire: quality of life (QoL-AD) | Up to 4 months | — |
| Stress test | Up to 4 months | Measuring the effect of training on the physiological performance by determining the maximum power of the effort tolerated |
| Measuring the effect of training on the physiological performance with a walk test of 6 minutes. | Up to 4 months | — |
Countries
Martinique
Outcome results
None listed